1.78k followers • 12 symbols Watchlist by Yahoo Finance
This basket consists of stocks that benefit from the needs of aging baby boomers.
The Procter & Gamble Company
UnitedHealth Group Incorporated
Royal Caribbean Cruises Ltd.
Service Corporation International
Matthews International Corporation
LifePoint Health, Inc.
We searched, using our Zacks Stock Screener, for large-cap dividend stocks investors might want to buy after the U.S. Federal Reserve cut interest rates for the second time...
A BBC investigation recently discovered dozens of YouTube videos promoting fake cancer cures. Could Google's YouTube lose advertisers?
Most of the cruise operators are bearing the brunt of high expenses for quite some time. Increase in oil prices will further elevate their expenses.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Procter & Gamble stock trades at 24.7x its fiscal 2020 estimated core EPS of $4.85. The stock trades at 23.2x its fiscal 2021 estimated core EPS of $5.17.
Church & Dwight (CHD) stock has risen 9.5% on a YTD (year-to-date) basis as of September 13. However, the stock lags its peers by a wide margin.
Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc . The combination of two of the world's biggest pharmaceutical companies, which was announced in June, would feature a portfolio that includes the world's top-selling medicine - AbbVie's rheumatoid arthritis drug Humira - as well as its cancer drugs and Allergan's blockbuster wrinkle treatment, Botox, and big-selling dry eye drug Restasis.
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Procter & Gamble's (PG) focus on improving its product portfolio through strategic initiatives bodes well. Also, the company is on track with its cost-saving plans.